Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 7.50
KYTH's Cash to Debt is ranked higher than
67% of the 723 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.47 vs. KYTH: 7.50 )
Ranked among companies with meaningful Cash to Debt only.
KYTH' s Cash to Debt Range Over the Past 10 Years
Min: 3.54  Med: 14.52 Max: No Debt
Current: 7.5
Equity to Asset 0.75
KYTH's Equity to Asset is ranked higher than
69% of the 674 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. KYTH: 0.75 )
Ranked among companies with meaningful Equity to Asset only.
KYTH' s Equity to Asset Range Over the Past 10 Years
Min: -2.57  Med: -0.63 Max: 0.75
Current: 0.75
-2.57
0.75
F-Score: 5
Z-Score: 20.68
M-Score: -52.62
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -37555.21
KYTH's Operating margin (%) is ranked lower than
100% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.51 vs. KYTH: -37555.21 )
Ranked among companies with meaningful Operating margin (%) only.
KYTH' s Operating margin (%) Range Over the Past 10 Years
Min: -391.04  Med: -182.55 Max: -83.54
Current: -37555.21
-391.04
-83.54
Net-margin (%) -39118.06
KYTH's Net-margin (%) is ranked lower than
100% of the 684 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.44 vs. KYTH: -39118.06 )
Ranked among companies with meaningful Net-margin (%) only.
KYTH' s Net-margin (%) Range Over the Past 10 Years
Min: -357.2  Med: -186.92 Max: -85.88
Current: -39118.06
-357.2
-85.88
ROE (%) -101.25
KYTH's ROE (%) is ranked lower than
94% of the 711 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.23 vs. KYTH: -101.25 )
Ranked among companies with meaningful ROE (%) only.
KYTH' s ROE (%) Range Over the Past 10 Years
Min: -129.61  Med: -88.54 Max: -47.46
Current: -101.25
-129.61
-47.46
ROA (%) -72.72
KYTH's ROA (%) is ranked lower than
95% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. KYTH: -72.72 )
Ranked among companies with meaningful ROA (%) only.
KYTH' s ROA (%) Range Over the Past 10 Years
Min: -97.98  Med: -50.79 Max: -38.51
Current: -72.72
-97.98
-38.51
ROC (Joel Greenblatt) (%) -6301.11
KYTH's ROC (Joel Greenblatt) (%) is ranked lower than
96% of the 729 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.81 vs. KYTH: -6301.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KYTH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -27062.87  Med: -10427.08 Max: -3013.33
Current: -6301.11
-27062.87
-3013.33
» KYTH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

KYTH Guru Trades in Q1 2015

George Soros 54,194 sh (New)
RS Investment Management 429,011 sh (+19.38%)
» More
Q2 2015

KYTH Guru Trades in Q2 2015

Paul Tudor Jones 6,939 sh (New)
Mario Gabelli 75,100 sh (New)
RS Investment Management Sold Out
George Soros Sold Out
» More
Q3 2015

KYTH Guru Trades in Q3 2015

Mario Gabelli 259,500 sh (+245.54%)
Paul Tudor Jones Sold Out
» More
Q4 2015

KYTH Guru Trades in Q4 2015

Mario Gabelli Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KYTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on KYTHERA Biopharmaceuticals Inc

Mario Gabelli Comments on Kythera Biopharmaceuticals Inc. - Oct 19, 2015

Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH)(3.4%) (KYTH – $74.98 – NASDAQ), based in Westlake Village, California, is a global biopharmaceutical company that focuses on developing and commercializing medical aesthetics products. On June 17, 2015, Allergan announced that it would acquire Kythera in a merger worth $1.9 billion or $75 per share. Initially, the transaction was to be comprised of cash and stock, but on August 5, Allergan amended the terms of the offering to all cash. The transaction closed on October 1, 2015, after receiving regulatory and shareholder approvals.



From Mario Gabelli (Trades, Portfolio)'s third quarter 2015 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about KYTHERA Biopharmaceuticals Inc

Mario Gabelli Comments on Kythera Biopharmaceuticals Inc. Guru stock highlight
Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH)(3.4%) (KYTH – $74.98 – NASDAQ), based in Westlake Village, California, is a global biopharmaceutical company that focuses on developing and commercializing medical aesthetics products. On June 17, 2015, Allergan announced that it would acquire Kythera in a merger worth $1.9 billion or $75 per share. Initially, the transaction was to be comprised of cash and stock, but on August 5, Allergan amended the terms of the offering to all cash. The transaction closed on October 1, 2015, after receiving regulatory and shareholder approvals. Read more...

Ratios

vs
industry
vs
history
P/B 13.44
KYTH's P/B is ranked lower than
99.99% of the 928 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.54 vs. KYTH: 13.44 )
Ranked among companies with meaningful P/B only.
KYTH' s P/B Range Over the Past 10 Years
Min: 6.69  Med: 11.83 Max: 17.83
Current: 13.44
6.69
17.83
P/S 7498.00
KYTH's P/S is ranked lower than
99.99% of the 929 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.60 vs. KYTH: 7498.00 )
Ranked among companies with meaningful P/S only.
KYTH' s P/S Range Over the Past 10 Years
Min: 9.55  Med: 28.67 Max: 7538
Current: 7498
9.55
7538
Current Ratio 8.13
KYTH's Current Ratio is ranked higher than
89% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. KYTH: 8.13 )
Ranked among companies with meaningful Current Ratio only.
KYTH' s Current Ratio Range Over the Past 10 Years
Min: 1.81  Med: 5.22 Max: 11.36
Current: 8.13
1.81
11.36
Quick Ratio 7.96
KYTH's Quick Ratio is ranked higher than
89% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. KYTH: 7.96 )
Ranked among companies with meaningful Quick Ratio only.
KYTH' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 5.22 Max: 11.36
Current: 7.96
1.81
11.36
Days Inventory 20.00
KYTH's Days Inventory is ranked higher than
95% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.42 vs. KYTH: 20.00 )
Ranked among companies with meaningful Days Inventory only.
KYTH' s Days Inventory Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 20
Days Payable 145.00
KYTH's Days Payable is ranked higher than
80% of the 563 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 72.59 vs. KYTH: 145.00 )
Ranked among companies with meaningful Days Payable only.
KYTH' s Days Payable Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 145

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.47
KYTH's Price/Net Cash is ranked lower than
61% of the 284 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.02 vs. KYTH: 14.47 )
Ranked among companies with meaningful Price/Net Cash only.
KYTH' s Price/Net Cash Range Over the Past 10 Years
Min: 5.66  Med: 10.68 Max: 32.33
Current: 14.47
5.66
32.33
Price/Net Current Asset Value 13.71
KYTH's Price/Net Current Asset Value is ranked lower than
72% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.70 vs. KYTH: 13.71 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KYTH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 5.43  Med: 9.23 Max: 23.26
Current: 13.71
5.43
23.26
Price/Tangible Book 13.44
KYTH's Price/Tangible Book is ranked lower than
88% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.76 vs. KYTH: 13.44 )
Ranked among companies with meaningful Price/Tangible Book only.
KYTH' s Price/Tangible Book Range Over the Past 10 Years
Min: 5.42  Med: 8.74 Max: 23.14
Current: 13.44
5.42
23.14
Price/Median PS Value 258.55
KYTH's Price/Median PS Value is ranked lower than
100% of the 899 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.15 vs. KYTH: 258.55 )
Ranked among companies with meaningful Price/Median PS Value only.
KYTH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.4  Med: 0.67 Max: 259.69
Current: 258.55
0.4
259.69
Earnings Yield (Greenblatt) (%) -6.00
KYTH's Earnings Yield (Greenblatt) (%) is ranked lower than
83% of the 720 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. KYTH: -6.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KYTH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -17.4  Med: 0.00 Max: 0
Current: -6
-17.4
0

More Statistics

Revenue(Mil) $23
EPS $ -4.74
Short Percentage of Float6.97%
52-Week Range $29.86 - 76.31
Shares Outstanding(Mil)26.27

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:KYT.Germany,
KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.
» More Articles for KYTH

Headlines

Articles On GuruFocus.com
The Gabelli ABC Fund Merger and Arbitrage Shareholder Commentary for Q4 Jan 29 2016 
Mario Gabelli Comments on Kythera Biopharmaceuticals Inc. Oct 19 2015 

More From Other Websites
Is Ellie Mae Inc (ELLI) A Good Stock To Buy? Dec 01 2015
Should You Buy Kennametal Inc. (KMT)? Nov 27 2015
KYTHERA® Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat... Oct 08 2015
Allergan Successfully Completes Kythera Acquisition; Adds Game-Changing KYBELLA Treatment for... Oct 08 2015
ALLERGAN PLC. Financials Oct 06 2015
XBI’s Top Ten Small-Cap Stocks Perform on Par with Large-Caps Oct 02 2015
KYTHERA Biopharmaceuticals, Inc. Earnings Q2, 2015 Oct 02 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement,... Oct 01 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Sep 28 2015
KYTHERA Files IND Application for Male Hair Loss Treatment Sep 23 2015
KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat... Sep 22 2015
KYTHERA Files Regulatory Application for Kybella in EU Aug 19 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 18 2015
KYTHERA(R) Biopharmaceuticals Submits Marketing Authorization Application in the European Union for... Aug 18 2015
KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update Aug 06 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 06 2015
Allergan reports better-than-expected revenue Aug 06 2015
What to Expect From Allergan Earnings Aug 05 2015
Allergan and KYTHERA Announce That Pending Transaction Will Now be for All-Cash Consideration Aug 05 2015
KYTHERA BIOPHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Aug 05 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK